Can Moderna Pull Off More Disruptive Innovation? Flu And RSV Shots Are Next Test
Analysts Skeptical About Taking On Established Players
Executive Summary
Moderna needs to develop new mRNA-based therapies beyond COVID-19, and flu and RSV will be the big readouts in 2023.
You may also be interested in...
Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option
The company will pay Moderna $250m upfront to develop and commercialize a personalized cancer vaccine for melanoma in combination with Keytruda.
Pfizer’s RSV Vaccine Shows Efficacy In Older Adults, Setting Up Showdown With GSK
Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.